Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 910, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174436
Keywords
Amphotericin B; Diagnosis; Drug repurposing; Host-directed therapy; Leishmaniasis; Nanotechnology
Categories
Funding
- University Grants Commission (UGC) , New Delhi
Ask authors/readers for more resources
Leishmaniasis is considered a neglected tropical disease by WHO and ranks second to malaria in terms of lethality. Accurate diagnosis is crucial due to involvement of multiple Leishmania species. New treatment methods for leishmaniasis include host-directed therapies, drug repurposing, nanotechnology, and combinational therapy.
Leishmaniasis is regarded as a neglected tropical disease by World Health Organization (WHO) and is ranked next to malaria as the deadliest protozoan disease. The primary causative agents of the disease comprise of diverse leishmanial species sharing clinical features ranging from skin abrasions to lethal infection in the visceral organs. As several Leishmania species are involved in infection, the role of accurate diagnosis becomes pivotal in adding new dimensions to anti-leishmanial therapy. Diagnostic methods must be fast, reliable, easy to perform, highly sensitive, and specific to differentiate among similar parasitic diseases. Herein, we present the conventional and recent approaches impended for the disease diagnosis and their sensitivity, specificity, and clinical application in parasite detection. Furthermore, we have also elaborated various new methods to cure leishmaniasis, which include host-directed therapies, drug repurposing, nanotechnology, and combinational therapy. This review addresses novel techniques and innovations in leishmaniasis, which can aid in unraveling new strategies to fight against the deadly infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available